Syndax Pharmaceuticals/$SNDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Ticker

$SNDX
Sector
Primary listing

Employees

270

SNDX Metrics

BasicAdvanced
$1.4B
-
-$3.89
0.73
-

What the Analysts think about SNDX

Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.

Bulls say / Bears say

Revuforj net product revenue reached $28.6 million in Q2 2025, a 43% increase from the previous quarter, showing strong commercial uptake since launch.
The FDA granted Priority Review for the supplemental NDA for revumenib in relapsed/refractory mNPM1 AML, setting a PDUFA action date of October 25, 2025—creating a near-term regulatory catalyst.
In the BEAT AML trial, revumenib combined with venetoclax and azacitidine achieved a 100% overall response rate and a 95% composite complete remission rate in newly diagnosed mNPM1 and KMT2Ar AML patients, demonstrating impressive efficacy.
Syndax posted a net loss of $71.8 million for Q2 2025 and burned through about $84 million in cash, bringing cash and investments down to $517.9 million, which could strain its financial runway if growth slows.
R&D expenses for Q2 2025 were $62.2 million and SG&A expenses were $43.8 million, totaling $106 million—more than double the quarter's revenue—highlighting significant operating leverage risk.
Revuforj treatment shows a 29% rate of differentiation syndrome, including fatal outcomes, posing serious safety and tolerability issues.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

SNDX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SNDX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SNDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs